NASDAQ:GMAB - Genmab A/S Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $38.71
  • Forecasted Upside: 0.95 %
  • Number of Analysts: 14
  • Breakdown:
  • 2 Sell Ratings
  • 5 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$38.35
▲ +0.03 (0.08%)
1 month | 3 months | 12 months
Get New Genmab A/S Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GMAB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GMAB

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$38.71
▲ +0.95% Upside Potential
This price target is based on 14 analysts offering 12 month price targets for Genmab A/S in the last 3 months. The average price target is $38.71, with a high forecast of $44.00 and a low forecast of $35.00. The average price target represents a 0.95% upside from the last price of $38.35.
Hold
The current consensus among 14 polled investment analysts is to hold stock in Genmab A/S. This rating has held steady since August 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/12/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/10/2019
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/9/2019
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/8/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 3 hold ratings
  • 1 sell ratings
6/6/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 2 sell ratings
9/4/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 5 hold ratings
  • 2 sell ratings
11/3/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 5 hold ratings
  • 2 sell ratings
12/3/2020

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 5 hold ratings
  • 2 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/25/2020HC WainwrightLower Price TargetBuy$45.00 ➝ $44.00Low
i
Rating by Ram Selvaraju at HC Wainwright
11/16/2020UBS GroupReiterated RatingBuyLow
i
11/5/2020Morgan StanleyBoost Price TargetOverweight$35.00 ➝ $37.00Low
i
11/5/2020HC WainwrightBoost Price TargetBuy$42.00 ➝ $45.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
10/27/2020The Goldman Sachs GroupBoost Price TargetNeutral$37.00High
i
10/13/2020Morgan StanleyBoost Price TargetOverweight$32.00 ➝ $35.00Low
i
9/23/2020HC WainwrightBoost Price TargetBuy$41.00 ➝ $42.00High
i
Rating by Ram Selvaraju at HC Wainwright
9/23/2020Bryan, Garnier & CoDowngradeNeutral ➝ SellHigh
i
9/8/2020SVB LeerinkInitiated CoverageMarket Perform$35.00Low
i
Rating by J. Chang at SVB Leerink LLC
8/24/2020TruistBoost Price Target$39.00 ➝ $41.00Low
i
8/21/2020HC WainwrightBoost Price TargetBuy$40.00 ➝ $41.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
8/13/2020Royal Bank of CanadaBoost Price TargetOutperform$35.00 ➝ $38.00Low
i
8/13/2020Morgan StanleyBoost Price TargetOverweight$30.00 ➝ $32.00High
i
8/13/2020HC WainwrightReiterated RatingBuyHigh
i
Rating by Ram Selvaraju at HC Wainwright
7/17/2020HC WainwrightReiterated RatingBuy$40.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
7/2/2020Societe GeneraleInitiated CoverageSellLow
i
6/30/2020HC WainwrightReiterated RatingBuy$40.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
6/25/2020Credit Suisse GroupDowngradeOutperform ➝ NeutralLow
i
6/19/2020Royal Bank of CanadaBoost Price TargetOutperform$27.00 ➝ $35.00Low
i
6/12/2020JPMorgan Chase & Co.Reiterated RatingOverweightLow
i
6/11/2020BarclaysReiterated RatingOverweightLow
i
6/11/2020SunTrust BanksBoost Price TargetBuy$36.00 ➝ $39.00Medium
i
6/11/2020HC WainwrightBoost Price TargetBuy$34.00 ➝ $40.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
6/3/2020BarclaysReiterated RatingOverweightMedium
i
6/3/2020Bryan, Garnier & CoDowngradeBuy ➝ NeutralLow
i
6/2/2020SunTrust BanksBoost Price TargetBuy$30.00 ➝ $36.00Low
i
6/2/2020DanskeDowngradeBuy ➝ HoldLow
i
6/1/2020HC WainwrightReiterated RatingPositive ➝ Buy$29.00 ➝ $34.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
5/26/2020UBS GroupUpgradeNeutral ➝ BuyLow
i
5/7/2020SunTrust BanksBoost Price TargetBuy$28.00 ➝ $30.00Low
i
5/7/2020HC WainwrightBoost Price TargetBuy$28.00 ➝ $29.00Low
i
Rating by Ram Selvaraju at HC Wainwright
5/1/2020HC WainwrightReiterated RatingBuy$28.00High
i
Rating by Ram Selvaraju at HC Wainwright
4/23/2020Credit Suisse GroupInitiated CoverageOutperformLow
i
4/15/2020Morgan StanleyLower Price TargetOverweight$31.00 ➝ $30.00Low
i
4/15/2020HC WainwrightLower Price TargetBuy$29.00 ➝ $28.00Low
i
Rating by Ram Selvaraju at HC Wainwright
4/6/2020Royal Bank of CanadaReiterated RatingBuy$27.00Medium
i
3/4/2020HC WainwrightReiterated RatingBuy$29.00Low
i
Rating by Ram Selvaraju at HC Wainwright
2/24/2020HC WainwrightReiterated RatingBuy$25.00 ➝ $29.00Low
i
Rating by Ram Selvaraju at HC Wainwright
2/20/2020Morgan StanleyBoost Price TargetOverweight$30.00 ➝ $31.00Medium
i
2/11/2020HC WainwrightReiterated RatingBuy$25.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
1/22/2020HC WainwrightReiterated RatingBuy$25.00Low
i
Rating by Ram Selvaraju at HC Wainwright
1/13/2020SunTrust BanksInitiated CoverageBuyMedium
i
12/12/2019Deutsche Bank AktiengesellschaftDowngradeBuy ➝ HoldHigh
i
12/11/2019HC WainwrightReiterated RatingBuy$25.00High
i
Rating by Ram Selvaraju at HC Wainwright
12/4/2019HC WainwrightReiterated RatingBuy$25.00Low
i
Rating by Ram Selvaraju at HC Wainwright
11/20/2019HC WainwrightReiterated RatingBuy$25.00Low
i
Rating by Ram Selvaraju at HC Wainwright
10/16/2019HC WainwrightBoost Price TargetBuy$24.00 ➝ $25.00Low
i
Rating by Ram Selvaraju at HC Wainwright
9/27/2019HC WainwrightSet Price TargetBuy$24.00Low
i
Rating by Ram Selvaraju at HC Wainwright
9/16/2019HC WainwrightReiterated RatingBuy$24.00Low
i
Rating by R. Selvaraju at HC Wainwright
9/13/2019Bank of AmericaUpgradeNeutral ➝ BuyMedium
i
9/12/2019JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$23.00Low
i
8/26/2019HC WainwrightReiterated RatingBuyLow
i
Rating by R. Selvaraju at HC Wainwright
8/12/2019GuggenheimInitiated CoverageBuy ➝ BuyMedium
i
8/12/2019Royal Bank of CanadaInitiated CoverageOutperform ➝ Outperform$23.00Low
i
8/12/2019Morgan StanleyInitiated CoverageOverweight ➝ OverweightLow
i
(Data available from 12/3/2015 forward)
Genmab A/S logo
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). Its products under development include Ofatumumab to treat CLL and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, and amyloidosis; Tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies. The company's products under development also comprise Teprotumumab for the treatment of Graves' orbitopathy; Camidanlumab tesirine (ADCT-301) to treat lymphoma, solid tumors, and acute myeloid leukemia (AML); HuMax-IL8 (BMS-986253) for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 to treat AML; JNJ-64007957 and JNJ-64407564 for MM; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs, including naked, bispecific, and immune effector function enhanced antibodies. The company has a commercial license and collaboration agreement with Seattle Genetics, Inc. to co-develop tisotumab vedotin, an antibody-drug conjugate; and a strategic collaboration agreement with Tempus to advance various disease targets and biomarkers, as well as Rentschler Biopharma SE. It also has a collaboration agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications; CureVac AG for the research and development of differentiated mRNA-based antibody products; and Tavotek Biotherapeutics and AbbVie. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.
Read More

Today's Range

Now: $38.35
$38.26
$38.68

50 Day Range

MA: $36.31
$33.66
$39.63

52 Week Range

Now: $38.35
$16.24
$39.81

Volume

262,619 shs

Average Volume

650,345 shs

Market Capitalization

$25.14 billion

P/E Ratio

29.73

Dividend Yield

N/A

Beta

0.92